Stocktoria
SIGA TECHNOLOGIES INC SIGA
SIGA TECHNOLOGIES INC (SIGA) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 15.34% (safety: at-risk). FY2025 revenue was $94.6M at a 24.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -4.03 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.888 |
| Retained earnings / assets | -0.196 |
| EBIT / assets | 0.108 |
| Equity / liabilities | 9.63 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SIGA | SIGA TECHNOLOGIES INC | 5/9 | 16.02 | 12.1 | -31.8% |
| CYTK | CYTOKINETICS INC | 3/9 | -7.91 | — | +376.6% |
| SPRY | ARS Pharmaceuticals, Inc. | 3/9 | -1.13 | — | -5.5% |
| NRIX | Nurix Therapeutics, Inc. | 3/9 | 1.2 | — | +54% |
| ZYME | Zymeworks Inc. | 5/9 | -3.24 | — | +38.9% |
| ZVRA | ZEVRA THERAPEUTICS, INC. | 5/9 | -0.84 | 9 | +350.9% |
| ARCT | Arcturus Therapeutics Holdings Inc. | 1/9 | 0.81 | — | -46.1% |
About SIGA TECHNOLOGIES INC
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
FAQ
Is SIGA financially healthy?
SIGA TECHNOLOGIES INC's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SIGA pay a dividend, and is it safe?
Yes. SIGA TECHNOLOGIES INC pays a dividend yielding about 15.34% with a 185.2% payout ratio, rated “at-risk” for safety.
How profitable is SIGA?
In FY2025, SIGA TECHNOLOGIES INC had a net margin of 24.6% and a return on equity of 11.7%.
Is SIGA overvalued or undervalued?
SIGA TECHNOLOGIES INC trades at about 9.0× trailing earnings — near its 10-year norm (10-year range 1.3×–36.8×, median 9.1×). Stocktoria reports the data, not buy/sell advice.
Is SIGA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SIGA TECHNOLOGIES INC: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 12.1×, a dividend yield of 15.34%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.